Autopsy report · NCT03786926
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Cause of deathFunding or business
“2018-689-00US1 has been halted by HUTCHMED based on strategic evaluation of the clinical development of HMPL-689 in the United States, Europe, and Australia.”
Life of this trial
- Registered 8 months before it started.
- Ran for about 4 years 10 months before it stopped.
- 53 participants enrolled.
- Results were posted on the registry 1 year after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Hutchmed
- Sponsor type
- Industry
- Conditions
- Lymphoma
- Interventions
- HMPL-689
- Participants
- 53
- Sites
- 27
- Countries
- Finland, France, Italy, Poland, Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.